![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/07/10/2911053/0/en/Ocuphire-Pharma-to-Highlight-APX3330-for-Diabetic-Retinopathy-at-Two-Scientific-Meetings-in-July.html
https://www.globenewswire.com/news-release/2024/06/06/2894586/0/en/Ocuphire-Pharma-Announces-Presentations-on-the-Development-of-APX3330-for-Diabetic-Retinopathy-at-Retina-Meetings-in-June.html
https://www.globenewswire.com/news-release/2024/05/10/2879589/0/en/Ocuphire-Pharma-Announces-Financial-Results-for-First-Quarter-2024-and-Provides-Corporate-Update.html
https://www.globenewswire.com/news-release/2024/05/06/2875782/0/en/Ocuphire-Pharma-Announces-Presentation-on-APX3330-at-the-ARVO-2024-Annual-Meeting.html
https://www.globenewswire.com/news-release/2024/05/03/2875073/0/en/Ocuphire-Pharma-to-Present-at-the-Aegis-Virtual-Conference.html
https://www.globenewswire.com/news-release/2024/04/22/2866824/0/en/Ocuphire-Pharma-Announces-APX3330-Presentation-at-ARVO-2024-Annual-Meeting.html
https://www.globenewswire.com/news-release/2024/04/11/2861621/0/en/First-Patient-Enrolled-in-LYNX-2-Phase-3-Study-Evaluating-Phentolamine-Ophthalmic-Solution-0-75-PS-for-the-Treatment-of-Decreased-Visual-Acuity-Under-Low-Light-Conditions-Following.html
https://www.globenewswire.com/news-release/2024/03/08/2843088/0/en/Ocuphire-Pharma-Announces-Financial-Results-for-Fourth-Quarter-and-Full-Year-2023-and-Provides-Corporate-Update.html
https://www.globenewswire.com//news-release/2024/02/23/2834435/0/en/Ocuphire-Pharma-to-Present-in-the-BIO-CEO-Investor-Conference.html
https://www.globenewswire.com//news-release/2024/02/15/2830386/0/en/Ocuphire-Pharma-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html